<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098358</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-02-C04-201</org_study_id>
    <nct_id>NCT00098358</nct_id>
  </id_info>
  <brief_title>Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Critical Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Critical Therapeutics</source>
  <brief_summary>
    <textblock>
      Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4)
      is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4
      is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase.
      This study will test the safety and efficacy of zileuton in the treatment of facial acne.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of inflammatory lesions</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of non-inflammatory lesions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total numbers of lesions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sebum production</measure>
  </secondary_outcome>
  <enrollment>90</enrollment>
  <condition>Acne Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zileuton</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe facial acne vulgaris

          -  20 to 60 facial inflammatory lesions

          -  10 to 200 facial non-inflammatory lesions

          -  No more than 3 facial nodular cystic lesions

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Use of systemic or topical acne therapy within 14 days of study

          -  Use of systemic retinoids within past 2 years

          -  Skin diseases that interfere with acne counts

          -  Active liver disease

          -  Screening elevations in liver function tests

          -  Positive serology for hepatitis B or C

          -  Use of theophylline, warfarin, or propranolol within 7 days of study

          -  Use of Singulair or Accolate within 14 days of study

          -  Female patients who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Newman, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Critical Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hersey Medical Center</name>
      <address>
        <city>Hersey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, Camera E, Cunliffe WJ. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol. 2003 May;139(5):668-70.</citation>
    <PMID>12756111</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>February 5, 2007</last_update_submitted>
  <last_update_submitted_qc>February 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2007</last_update_posted>
  <keyword>Leukotrienes</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

